Company intelligence / Profile preview

Microlin Bio

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

The company's lead candidate, anti-miR-21, demonstrated positive results in preclinical models of lung cancer[1]. The company focused on developing anti-microRNA therapeutics and had licensed technologies covering numerous microRNAs with over 138 pending and 132 granted patents[1].

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotide
Industry: Biotech

Partnerships

Ohio State University (exclusive worldwide license agreement for microRNA cancer discoveries and nucleic acid delivery technology)[5]

Beyond the preview

Go deeper on Microlin Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microlin Bio.

Explore the full profile